Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies

In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC imp...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pulm Circ
Hlavní autoři: Cartin-Ceba, Rodrigo, Halank, Michael, Ghofrani, Hossein-Ardeschir, Humbert, Marc, Mattson, John, Fritsch, Arno, Krowka, Michael
Médium: Artigo
Jazyk:Inglês
Vydáno: SAGE Publications 2018
Témata:
Research Letter
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5987907/
https://ncbi.nlm.nih.gov/pubmed/29565224
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2045894018769305
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky